August Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Assisted living operations and care management platform built for modern senior living communities, replacing paper-based workflows with AI-assisted assessments and digital care planning.
About
August Health is a San Francisco, California-based senior care technology company building a modern cloud-native platform for assisted living and memory care communities. Founded in 2019 and having raised over $14 million from investors including a16z and others, August Health targets the large segment of senior living communities still operating on paper-based or legacy software workflows. The company's platform digitizes resident assessments, care planning, incident reporting, medication management, and family communication in a design-forward interface built for use by care staff on mobile devices.\n\nA key differentiator for August Health is its use of AI to assist care staff in completing state-required assessments and care plans. The platform can generate draft care plan language based on assessment responses, reducing the documentation burden on caregivers while improving consistency and completeness of clinical records. This AI-assisted documentation capability is particularly valuable in assisted living, where staffing challenges and high turnover make efficient documentation workflows critical to operational quality.\n\nAugust Health competes with established vendors like Yardi Senior Living and MatrixCare but targets smaller independent communities and regional groups that find legacy platforms overly complex and expensive for their needs. The company's modern UX, mobile-first design, and AI-assisted features position it as a next-generation alternative in a market where much of the installed base runs on software designed before smartphones existed. As the senior care sector faces mounting staffing pressure, technology that reduces administrative burden on direct care staff is increasingly valued by operators.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.